Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCZ | Q05513 | 11/20 | 0.70 |
| ▸ | PRKCI | P41743 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17356385 | 0.85 | MAPT (0.73) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL12271891 | 0.84 | PRKCZ (0.68) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL13837782 | 0.82 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1HSD17B10 | |
| SCHEMBL17356378 | 0.80 | MAPT (0.72) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL14123479 | 0.79 | PRKCZ (0.66) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL10297769 | 0.79 | PRKCZ (0.70) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL12632700 | 0.78 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL31060884 | 0.78 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL13838035 | 0.76 | PRKCZ (0.83) | PRKCZPRKCIMAPTALDH1A1POLB | |
| SCHEMBL13837726 | 0.75 | PRKCZ (1.00) | PRKCZPRKCIMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301965-B2 | Method of treating ovarian cancer using a PKC inhibitor | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366883-A1 | METHOD OF TREATING OVARIAN CANCER USING A PKC INHIBITOR | PRKD1, PRKCI, ACP3 | PRKCZ 16/4885PRKCI 2/4885MAPT 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.